ACP3-targeted PET/CT imaging to detect prostate cancer lesions
ACP3 Targeted -PET/ CT in Prostate Cancer
NA · Guilin Medical University, China · NCT07559201
This will see if ACP3 PET/CT can find more tumor lesions than standard PSMA/FDG PET/CT in adults with prostate cancer or suspected recurrence.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Guilin Medical University, China (other) |
| Locations | 1 site (Guilin, Guangxi) |
| Trial ID | NCT07559201 on ClinicalTrials.gov |
What this trial studies
ACP3 is a novel PET radiotracer designed to target prostate cancer lesions. Participants undergo contemporaneous ACP3 PET/CT alongside standard-of-care PSMA/FDG PET/CT for initial staging, detection of metastases, or suspected recurrence. Tumor uptake will be quantified using SUVmax and the number of positive lesions will be recorded by visual interpretation. Diagnostic accuracy of ACP3 PET/CT will be calculated and compared directly with the standard imaging methods.
Who should consider this trial
Good fit: Adults (18 years or older) with newly diagnosed prostate cancer, highly suspected recurrence, or previously treated metastatic disease who are scheduled for both ACP3 and PSMA/FDG PET/CT and can provide informed consent.
Not a fit: Patients who cannot undergo PET/CT imaging, cannot provide informed consent, or whose tumors do not express the ACP3 target may not receive benefit from this imaging approach.
Why it matters
Potential benefit: If successful, ACP3 PET/CT could provide more accurate, noninvasive detection of prostate cancer lesions to improve staging and treatment planning.
How similar studies have performed: PSMA and FDG PET/CT are well established and diagnostically effective, while ACP3 is a newer tracer with limited human data, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (aged 18 years or older); * Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report); * Patients who had scheduled both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans; * Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * The inability or unwillingness of the research participant or legal representative to provide written informed consent.
Where this trial is running
Guilin, Guangxi
- The First Affliated Hospital of Guilin Medical University — Guilin, Guangxi, China (RECRUITING)
Study contacts
- Study coordinator: Xingyu Mu, PhD
- Email: muxingyu1992@hotmail.com
- Phone: 86 13347631119
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, prostate cancer, PET/CT, ACP3